Harmony Biosciences Holdings, Inc. (HRMY) Guidance & Earnings Results
On 2026-08-04 Harmony Biosciences Holdings, Inc. reaffirmed guidance: "WAKIX net revenue guidance $1.0B-$1.04B for…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HRMYHarmony Biosciences Holdings, Inc.Follow HRMY — free
—
Price chart with a free account
- Market cap
- 2.1B
- P/E TTM
- 11.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 4 Aug 26 | Reaffirmed | WAKIX net revenue guidance $1.0B-$1.04B for FY2026 · full year |
| 16 Jul 26 | Reaffirmed | FY2026 net revenue guidance $1.0B-$1.04B · full year |
| 12 Jan 26 | Raised | FY26 WAKIX revenue $1.0-1.04B · full year |
| 4 Nov 25 | Raised | Revenue guidance raised from $820-$860M to $845-$865M · full year |
| 23 Oct 25 | Raised | Revenue guidance raised from $820-$860M to $845-$865M · full year |
| 5 Aug 25 | Reaffirmed | FY2025 net revenue $820-$860 million · full year |
Harmony Biosciences Holdings, Inc. — questions
- What guidance did Harmony Biosciences Holdings, Inc. give?
- On 2026-08-04: "WAKIX net revenue guidance $1.0B-$1.04B for FY2026"
- When does Harmony Biosciences Holdings, Inc. report earnings?
- Harmony Biosciences Holdings, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Harmony Biosciences Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.